• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Multiple Myeloma: 8 Frequently Asked Patient Questions

by | Aug 27, 2024 | Uncategorized

Source: CureToday articles Questions about multiple myeloma regarding treatment options, bone strength and other associated comorbidities were answered by an expert. Read More

My Olympics With Multiple Myeloma

by | Aug 12, 2024 | Uncategorized

Source: CureToday articles After my myeloma diagnosis, each day is my own personal Olympics, filled with trials and triumph. Read More

FDA Approves Darzalex Faspro Regimen for Some With Multiple Myeloma

by | Jul 30, 2024 | Uncategorized

Source: CureToday articles The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for select patients newly diagnosed with multiple myeloma. Read More

Myeloma-Related Questions to Ask After Diagnosis

by | Jul 29, 2024 | Uncategorized

Source: CureToday articles From finding reputable info to asking, “Do I really need all these drugs?” experts weighed in on important questions to ask after a myeloma diagnosis. Read More

What I’m Glad I Knew (and Didn’t) With Myeloma

by | Jul 27, 2024 | Uncategorized

Source: CureToday articles When I fell in love, I didn’t know my husband would end up getting cancer, but I also glad I learned that normal people like me can make a difference. Read More

Isa-KRd Elicits Responses in Some With Newly Diagnosed Multiple Myeloma

by | Jul 25, 2024 | Uncategorized

Source: CureToday articles “Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®. Read More
« Older Entries
Next Entries »

Recent Content

  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Real-World Outcomes Show Efficacy, Safety of Ciltacabtagene Autoleucel in Relapsed, Refractory Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT